JP2016501523A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501523A5
JP2016501523A5 JP2015545446A JP2015545446A JP2016501523A5 JP 2016501523 A5 JP2016501523 A5 JP 2016501523A5 JP 2015545446 A JP2015545446 A JP 2015545446A JP 2015545446 A JP2015545446 A JP 2015545446A JP 2016501523 A5 JP2016501523 A5 JP 2016501523A5
Authority
JP
Japan
Prior art keywords
cancer
percentile
individual
telomere length
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015545446A
Other languages
English (en)
Japanese (ja)
Other versions
JP6359028B2 (ja
JP2016501523A (ja
Filing date
Publication date
Priority claimed from US13/802,035 external-priority patent/US9200327B2/en
Application filed filed Critical
Priority claimed from PCT/US2013/072302 external-priority patent/WO2014085632A1/en
Publication of JP2016501523A publication Critical patent/JP2016501523A/ja
Publication of JP2016501523A5 publication Critical patent/JP2016501523A5/ja
Application granted granted Critical
Publication of JP6359028B2 publication Critical patent/JP6359028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015545446A 2012-11-30 2013-11-27 テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー Active JP6359028B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261732263P 2012-11-30 2012-11-30
US61/732,263 2012-11-30
US201361780851P 2013-03-13 2013-03-13
US61/780,851 2013-03-13
US13/802,035 US9200327B2 (en) 2012-11-30 2013-03-13 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US13/802,035 2013-03-13
US201361798478P 2013-03-15 2013-03-15
US61/798,478 2013-03-15
US201361809228P 2013-04-05 2013-04-05
US61/809,228 2013-04-05
PCT/US2013/072302 WO2014085632A1 (en) 2012-11-30 2013-11-27 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018022923A Division JP2018099127A (ja) 2012-11-30 2018-02-13 テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー

Publications (3)

Publication Number Publication Date
JP2016501523A JP2016501523A (ja) 2016-01-21
JP2016501523A5 true JP2016501523A5 (enExample) 2017-01-19
JP6359028B2 JP6359028B2 (ja) 2018-07-18

Family

ID=50828470

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545446A Active JP6359028B2 (ja) 2012-11-30 2013-11-27 テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー
JP2018022923A Pending JP2018099127A (ja) 2012-11-30 2018-02-13 テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018022923A Pending JP2018099127A (ja) 2012-11-30 2018-02-13 テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー

Country Status (24)

Country Link
EP (4) EP3495495B1 (enExample)
JP (2) JP6359028B2 (enExample)
KR (3) KR102348240B1 (enExample)
CN (2) CN104937110A (enExample)
AU (4) AU2013352105B2 (enExample)
BR (1) BR112015012507B1 (enExample)
CA (1) CA2892445C (enExample)
CY (1) CY1124140T1 (enExample)
DK (2) DK3495495T3 (enExample)
ES (3) ES2972330T3 (enExample)
HR (2) HRP20181991T1 (enExample)
HU (1) HUE054053T2 (enExample)
IL (3) IL282112B (enExample)
LT (2) LT2925889T (enExample)
MX (1) MX362094B (enExample)
NZ (2) NZ748624A (enExample)
PL (2) PL2925889T3 (enExample)
PT (2) PT3495495T (enExample)
RS (1) RS61513B1 (enExample)
SG (1) SG11201504209YA (enExample)
SI (2) SI3495495T1 (enExample)
SM (1) SMT202100142T1 (enExample)
WO (1) WO2014085632A1 (enExample)
ZA (2) ZA201900759B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3029154T (pt) 2008-10-17 2017-12-06 Geron Corp Método para identificação de sensibilidade de um paciente à terapia de inibição da telomerase
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JPWO2018207952A1 (ja) * 2017-05-12 2020-04-16 国立大学法人九州大学 発毛及び/又は育毛用組成物
TWI879717B (zh) 2017-07-28 2025-04-11 美商傑龍公司 治療骨髓增生不良症候群之方法
EP3829651A4 (en) * 2018-07-31 2022-05-04 Geron Corporation METHODS OF IDENTIFYING PATIENTS WHO WILL BENEFIT FROM TREATMENT WITH A TELOMERASE INHIBITOR
GB201818792D0 (en) * 2018-11-19 2019-01-02 Telonostix Ltd Compounds for telomere length-related treatment of cancer
SG11202105573PA (en) 2018-11-29 2021-06-29 Geron Corp Methods of treating myelodysplastic syndrome
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
CN114306602B (zh) * 2020-09-28 2024-06-11 中国科学院上海营养与健康研究所 靶向tert在调节皮肤及毛发色素中的应用
CN115463122B (zh) * 2022-08-16 2025-03-25 吕梁学院 一种增强盐霉素抗癌活性的方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
JPH11276182A (ja) * 1997-12-26 1999-10-12 Chugai Pharmaceut Co Ltd 逆転写酵素モチーフを有する新規遺伝子
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
JP4515767B2 (ja) 2002-01-31 2010-08-04 ユニバーシティ・オブ・ユタ 非標的核酸依存性増幅の低減:反復核酸配列の増幅
US20040234961A1 (en) * 2002-04-22 2004-11-25 Fordyce Colleen A. Telomere length determination and applications
EP2474822A1 (en) 2003-01-24 2012-07-11 University of Utah Methods of predicting mortality risk by determining telomere length
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
RS56361B1 (sr) 2004-07-02 2017-12-29 Geron Corp Sinteza zaštićenih 3'-amino nukleozidnih monomera
JP2008536822A (ja) * 2005-03-25 2008-09-11 アルト ソリューションズ インコーポレーテッド テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療
WO2006113470A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
PT3029154T (pt) * 2008-10-17 2017-12-06 Geron Corp Método para identificação de sensibilidade de um paciente à terapia de inibição da telomerase
CA2748265C (en) 2008-12-22 2018-04-03 University Of Utah Research Foundation Monochrome multiplex quantitative pcr
US20110207128A1 (en) 2010-02-16 2011-08-25 Cawthon Richard M Methods and kits for determining biological age and longevity based on gene expression profiles
WO2012135125A1 (en) 2011-03-28 2012-10-04 Geron Corporation Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr

Similar Documents

Publication Publication Date Title
JP2016501523A5 (enExample)
JOP20210207A1 (ar) مركبات ترابطية مستهدفة
MX2023006334A (es) Ligandos dirigidos para compuestos terapeuticos.
WO2010141511A3 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
ES2686549T3 (es) Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
RU2016119999A (ru) Способы лечения онкологических заболеваний
HRP20210451T1 (hr) Dijagnostički markeri za liječenje staničnih poremećaja proliferacije inhibitorima telomeraza
WO2016115543A3 (en) Novel micro-dystrophins and related methods of use
CO7170127A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 m(lag-3) y usos de los mismos
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
JP2016074736A5 (enExample)
RU2016123086A (ru) Способы и композиции для лечения болезни хантингтона
JP2018508469A5 (enExample)
UA118014C2 (uk) Спосіб модифікації днк-мішені
JP2018502956A5 (enExample)
JP2017513908A5 (enExample)
JP2019527563A5 (enExample)
Bartas et al. Bioinformatics analyses and in vitro evidence for five and six stacked G-quadruplex forming sequences
CN103221542A (zh) miRNA用于诊断、预防、治疗和追踪涉及巨自噬异常的疾病的用途
JP2016540726A5 (enExample)
Hurtado et al. Análisis molecular del cáncer de colon esporádico
RU2013119459A (ru) Комплекс ipp в качестве маркера лечения эрлотинибом
CN106906213B (zh) 一种修饰的siRNA及其用途
JP2021500026A5 (enExample)
Huse et al. Yin and yang: cancer-implicated miRNAs that have it both ways